home / stock / glsi / glsi quote
Last: | $16.71 |
---|---|
Change Percent: | -0.72% |
Open: | $16.82 |
Close: | $16.71 |
High: | $16.98 |
Low: | $16.07 |
Volume: | 35,496 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.71 | $16.82 | $16.71 | $16.98 | $16.07 | 35,496 | 07-05-2024 |
$16.7 | $17.4878 | $16.7 | $17.4878 | $16.2711 | 36,686 | 07-04-2024 |
$16.7 | $17.4878 | $16.7 | $17.4878 | $16.2711 | 36,686 | 07-03-2024 |
$17.58 | $16.61 | $17.58 | $18.15 | $16.61 | 63,138 | 07-02-2024 |
$16.77 | $17.18 | $16.77 | $17.5 | $16.03 | 47,012 | 07-01-2024 |
$17.26 | $16.88 | $17.26 | $17.5 | $16.47 | 748,912 | 06-28-2024 |
$16.88 | $17.28 | $16.88 | $17.96 | $16.25 | 69,901 | 06-27-2024 |
$17.1 | $15.45 | $17.1 | $17.25 | $15.45 | 54,118 | 06-26-2024 |
$15.38 | $16.2601 | $15.38 | $16.5 | $15.38 | 26,521 | 06-25-2024 |
$15.5 | $16.63 | $15.5 | $16.99 | $15.32 | 37,303 | 06-24-2024 |
$16.27 | $14.99 | $16.27 | $17 | $14.99 | 41,808 | 06-21-2024 |
$15.3 | $15.77 | $15.3 | $16.48 | $15.1 | 55,137 | 06-20-2024 |
$15.97 | $17.12 | $15.97 | $18.7499 | $15.81 | 75,217 | 06-19-2024 |
$15.97 | $17.12 | $15.97 | $18.7499 | $15.81 | 75,217 | 06-18-2024 |
$17.44 | $15.22 | $17.44 | $18 | $15.22 | 131,612 | 06-17-2024 |
$14.76 | $15 | $14.76 | $15.47 | $14.575 | 17,200 | 06-14-2024 |
$14.85 | $14.37 | $14.85 | $14.85 | $14.2575 | 13,731 | 06-13-2024 |
$14.3 | $14.2279 | $14.3 | $14.956 | $14.21 | 24,400 | 06-12-2024 |
$14.19 | $14.98 | $14.19 | $14.98 | $14.19 | 27,553 | 06-11-2024 |
$14.81 | $14.18 | $14.81 | $15.2 | $13.91 | 17,253 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...
2024-05-11 10:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...